Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB

PHASE4CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 26, 2011

Primary Completion Date

July 28, 2016

Study Completion Date

August 23, 2016

Conditions
Chronic Hepatitis B
Interventions
DRUG

TDF

Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily

OTHER

Stop TDF

Participants will stop TDF therapy

Trial Locations (13)

10969

Leberzentrum am Checkpoint, Berlin

13353

Charite CVK, Berlin

20099

ifi Studien und Projekte GmbH, Hamburg

20246

Universitaetsklinikum Hamburg Eppendorf, Hamburg

30625

Medizinische Hochschule Hannover, Hanover

40237

Zentrum für HIV und Hepatitis, Düsseldorf

44623

Gastroenterologische Gemeinschaftspraxis, Herne

51375

Gemeinschaftspraxis Gastroenterologie, Leverkusen

60590

J.W. Goethe Universitaetsklinikum, Frankfurt

69120

Universitaetsklinik Heidelberg, Heidelberg

81377

Klinikum der LMU Grosshadern, München

89081

Universitaetsklinikum Ulm, Ulm

04103

Universitaetsklinikum Leipzig, Leipzig

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT01320943 - Stopping TDF Treatment After Long Term Virologic Suppression in HBeAg-negative CHB | Biotech Hunter | Biotech Hunter